Chapter 3 · Module 2 of 4 · Pharmacodynamics

Quantitative Pharmacodynamics

Emax, EC50, potency versus efficacy, the therapeutic index, and receptor reserve — the quantitative framework underlying dose-response relationships

Emax is the maximum effect a drug can produce — set by intrinsic efficacy and effector pathway capacity; no additional dose can exceed a drug's own Emax; partial agonists plateau below the system Emax regardless of dose
EC50 is the concentration producing 50% of Emax and quantifies potency — lower EC50 means greater potency (left shift); steep dose-response curves, where small dose changes produce large effect changes, characterize narrow therapeutic index drugs
Potency and efficacy are independent: a drug can be highly potent (low EC50) but have low efficacy (low Emax), or vice versa; the distinction is clinically critical — buprenorphine is more potent than morphine at the receptor but has a lower Emax as a partial agonist and cannot replace morphine for severe pain
The therapeutic index (TD50 ÷ ED50) quantifies the margin between effective and toxic doses; narrow therapeutic index drugs (warfarin, lithium, digoxin, phenytoin, aminoglycosides) require individual plasma concentration monitoring because population-based dosing is insufficient
Receptor reserve (spare receptors) exists when maximum tissue response is achieved at less than full receptor occupancy due to downstream signal amplification; this makes functional EC50 lower than binding Kd, causes potency to vary across tissues with different reserve sizes, and explains why irreversible antagonists depress Emax only after reserve is exhausted

Section 1 — Emax and EC50

Section 1

The Two Parameters of the Dose-Response Curve

Parameter 1

Emax — Efficacy Ceiling

Maximum effect a drug can produce
Determined by intrinsic efficacy and effector pathway capacity
Full agonist reaches system Emax
Partial agonist reaches a lower Emax regardless of dose
No amount of additional drug exceeds a drug's own Emax

Parameter 2

EC50 — Potency Measure

Concentration producing 50% of Emax
Lower EC50 = more potent = leftward curve shift
Steep curve = small dose change causes large effect change
Steep curves characterize narrow therapeutic index drugs
EC50 (functional assay) ≠ Kd (binding assay) when receptor reserve is present

Graded vs. Quantal Dose-Response Curves

Graded curve: continuous response measured in one preparation; parameters = Emax and EC50; answers "how much effect?" Quantal curve: all-or-none endpoint measured across a population; parameters = ED50, TD50, LD50; answers "what fraction of patients respond?" EC50 (graded) and ED50 (quantal) are different measurements that address different questions.

Section 2 — Potency versus Efficacy

Section 2

Potency and Efficacy — Independent Properties

Property	Measured By	Curve Appearance	Clinical Relevance
Potency	EC50 — lower = more potent	Curve shifts left (more potent) or right (less potent); plateau height unchanged	Matters when dose size must be minimized (e.g., inhaled drugs, transdermal patches)
Efficacy	Emax — higher = more efficacious	Plateau reaches higher (more efficacious) or lower (less efficacious); EC50 position unchanged	Matters when maximum effect is required — a more potent drug with lower Emax cannot substitute

Clinical Examples — Why the Distinction Is Essential

Morphine vs. codeine: same Emax (both full mu-opioid agonists), morphine approximately 10× more potent. Buprenorphine vs. morphine: buprenorphine is more potent (higher affinity, lower EC50) but has a lower Emax as a partial agonist — it cannot control severe pain requiring maximum opioid effect. Furosemide vs. hydrochlorothiazide: furosemide has a higher Emax for diuresis — the decisive difference for patients with severe heart failure or renal impairment where maximum natriuresis is required.

Section 3 — The Therapeutic Index

Section 3

Wide vs. Narrow Therapeutic Index

Definition

Therapeutic index = TD50 ÷ ED50 (or LD50 ÷ ED50 in animal studies). A larger TI means a wider margin between effective and toxic doses. In clinical practice, the therapeutic window is the range of plasma concentrations producing the desired therapeutic effect without unacceptable toxicity. Narrow TI drugs have overlapping effective and toxic plasma concentration ranges.

Wide Therapeutic Index

Safe Margin

Toxic dose substantially higher than effective dose
Standard population-based dosing is safe
Routine plasma level monitoring not required
Examples: penicillins, cephalosporins, most statins

Narrow Therapeutic Index

Tight Margin — Monitor

Toxic dose close to effective dose
Individual plasma concentration monitoring required
Warfarin — monitor INR
Lithium — monitor plasma levels; toxicity with dehydration
Digoxin — monitor levels and electrocardiogram
Phenytoin — nonlinear kinetics; monitor free levels
Aminoglycosides — nephrotoxicity, ototoxicity; monitor peaks and troughs

Section 4 — Receptor Reserve (Spare Receptors)

Section 4

Receptor Reserve and Its Pharmacodynamic Consequences

Core Concept

Maximum tissue response is achieved when only a fraction of receptors are occupied, because downstream signal amplification saturates the effector pathway at low occupancy. Receptors beyond that threshold are "spare." Consequence: EC50 (functional) is lower than Kd (binding) whenever receptor reserve is present — a drug appears more potent in functional assays than its binding affinity alone would predict.

Implication 1

Tissue-Dependent Potency

EC50 varies across tissues with different reserve sizes
EC50 cannot reliably estimate receptor Kd
Same drug appears more potent in tissues with larger reserve

Implication 2

Partial Agonists and Reserve

Large reserve: partial agonist may reach full Emax
Limited reserve: partial agonist shows ceiling effect
Buprenorphine — ceiling on respiratory depression (limited reserve) but meaningful analgesia (greater reserve in pain pathways)

Implication 3

Irreversible Antagonists

Reserve buffers against permanent receptor blockade
Emax preserved until reserve is exhausted
Then Emax falls steeply with further blockade
Aspirin: minimal platelet COX reserve — low doses fully suppress thromboxane A2 synthesis

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th edition	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th edition	McGraw-Hill, 2023
Stephenson RP	A modification of receptor theory	British Journal of Pharmacology and Chemotherapy, 1956; 11(4):379–393
Kenakin T	What is pharmacological affinity? Relevance to biased agonism and antagonism	Trends in Pharmacological Sciences, 2014; 35(9):434–441
Fudala PJ, Bridge TP, Herbert S, et al.	Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone	New England Journal of Medicine, 2003; 349(10):949–958
Mailman RB	GPCR functional selectivity has therapeutic impact	Trends in Pharmacological Sciences, 2007; 28(8):390–396
Kenakin T	Functional selectivity and biased receptor signaling	Journal of Pharmacology and Experimental Therapeutics, 2011; 336(2):296–302
Furchgott RF	The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes	Advances in Drug Research, 1966; 3:21–55